White Paper · Hemp · Federal Transition

Federal Hemp Transition: What Changes November 12 and What Waits Until December 11, 2026

Congress rewrote the federal definition of hemp in 2025, then split the start of that rewrite across two dates. This briefing explains what each date reaches, what remains unsettled, and why Illinois businesses face a state date that did not move.

By Lincoln Square Law · 11-minute read

The short answer for operators

Two federal dates now matter. On November 12, 2026, the new federal definition of hemp begins to apply, but only to intermediate and final hemp-derived cannabinoid products that contain cannabinoids the Cannabis sativa L. plant cannot naturally produce. On December 11, 2026, the rest of the rewrite is scheduled to apply, including the total-THC test and the 0.4-milligram-per-container limit for final products. Congress could change either date again, and as of this writing it has not.

Illinois businesses have a third consideration. The Illinois Hemp Act takes effect on November 12, 2026, and the Illinois Department of Revenue has said the State plans to enforce it on that date regardless of the federal delay. A product can therefore remain federal hemp through December 10 and still be treated as cannabis in Illinois from November 12.

What Section 781 changes in the federal definition

Section 781 of division B of Public Law 119-37, enacted November 12, 2025, amended the hemp definition in section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o). The amendment was written to take effect 365 days after enactment.

The amended definition replaces the delta-9 test with a total-tetrahydrocannabinols test. Hemp becomes the plant and its derivatives with a total THC concentration, including tetrahydrocannabinolic acid (THCA), of not more than 0.3 percent on a dry weight basis. THCA is the acid form of THC found in raw plant material. It converts to delta-9 THC when heated, which is why counting it changes the result for much smokable flower.

The new text then adds exclusions. Viable seeds from a plant above the total-THC limit are excluded. Intermediate hemp-derived cannabinoid products are excluded if they contain cannabinoids the plant cannot naturally produce, cannabinoids the plant can produce that were synthesized or manufactured outside the plant, or more than 0.3 percent combined total THC and other cannabinoids with similar effects as determined by the Secretary of Health and Human Services. An intermediate product marketed or sold as a final product, or directly to an end consumer, is also excluded. Final hemp-derived cannabinoid products are excluded on the same two cannabinoid-source grounds and if they contain more than 0.4 milligrams combined total per container of total THC and similar-effect cannabinoids (7 U.S.C. 1639o(1)(C), as amended).

The amendment also defines its key terms. A hemp-derived cannabinoid product is an intermediate or final product derived from hemp, other than industrial hemp, that contains cannabinoids and is intended for human or animal use. An intermediate product is one not yet in final form, or one meant to be mixed or prepared into another substance before use. Industrial hemp, grown for fiber, grain, seed oil, microgreens, and similar non-cannabinoid uses, is expressly included in hemp (7 U.S.C. 1639o(2), (3), as amended).

What Section 2019 does between November 12 and December 11

On September 2, 2026, the Continuing Appropriations and Extensions Act, 2027 became Public Law 119-103. Section 2019 of division B provides that, until December 11, 2026, the section 781 amendments apply only to products described in paragraphs (1)(C)(ii)(I) and (1)(C)(iv)(I) of the amended definition (Pub. L. 119-103, div. B, sec. 2019).

Those two paragraphs are the “not capable of being naturally produced” exclusions, one for intermediate products and one for final products. During the period from November 12 through December 10, the federal change therefore reaches products built on cannabinoids the plant cannot make. The Congressional Research Service describes this group as certain synthetic cannabinoids and states that, from November 12, products within the exclusion are to be classified as marijuana under the Controlled Substances Act (CRS In Focus IF13136, updated Sept. 28, 2026).

Section 2019 does not activate the other exclusions during that window. The total-THC test, the exclusion for plant-producible cannabinoids synthesized outside the plant, the intermediate-product limit, the rule for intermediates sold to consumers, and the container limit all wait until December 11.

What takes effect December 11 unless Congress acts

Section 2019 sets its own end date. It is not tied to whether Congress passes another funding bill. The same law funds the government only through December 11, 2026 (Pub. L. 119-103, div. A, sec. 106(3)), so funding legislation will be under consideration near that date. A new funding law would change the hemp schedule only if it amends section 2019 or section 781.

If nothing changes, the complete section 781 definition applies on December 11. Several bills introduced in Congress would delay the definition for two years or repeal it, and others would replace it with a regulatory framework. As of the CRS update dated September 28, 2026, none of those bills had been enacted, and the House-passed fiscal year 2027 agriculture appropriations bill did not contain a delay. We did not locate any enacted change through October 25, 2026.

The container test makes packaging a legal decision

For final products, the December 11 limit is measured per container, not per serving. The statute defines a container as the innermost wrapping, packaging, or vessel in direct contact with the final product in which it is enclosed for retail sale, such as a jar, bottle, bag, box, packet, can, carton, or cartridge. Bulk shipping containers and outer wrappings not essential to the final retail sale are excluded (7 U.S.C. 1639o(3)(C), (D), as amended).

That definition makes the package configuration part of the legal test. A product with a constant amount per serving can move across the line if the number of servings in the container changes. Formulation, fill count, beverage size, and cartridge capacity should be reviewed together, and a decision to change any of them should trigger a fresh classification.

What is still missing: the FDA lists

Section 781 also directed the Food and Drug Administration, within 90 days of enactment, to publish a list of cannabinoids capable of being naturally produced by the plant, a list of THC-class cannabinoids that occur naturally in the plant, a list of other cannabinoids with similar effects or marketed to have similar effects, and additional detail on the term “container” (Pub. L. 119-37, div. B, sec. 781(3)). CRS reported that, as of September 28, 2026, the lists had not been published. Our search of the Federal Register through October 25, 2026 did not locate them.

The gap matters most for the line between the November 12 and December 11 categories. Whether a cannabinoid is “not capable of being naturally produced” by the plant is a scientific and legal question. Cannabinoids that occur naturally in trace amounts but are typically made by converting another cannabinoid raise the hardest version of that question, because the answer decides whether a product is reached on November 12 or on December 11. Businesses should not rely on informal lists or marketing summaries for that call. Document the scientific basis for each cannabinoid’s classification and expect to revisit it if FDA publishes.

What falling outside the definition means federally

The 2018 Farm Bill removed hemp from the Controlled Substances Act definition of marijuana. When a plant or product no longer meets the hemp definition, it loses that exclusion. CRS states that products excluded by the new provisions are to be regulated as marijuana under the Controlled Substances Act once the provisions take effect. The Farm Bill’s interstate commerce protection likewise applies to hemp produced in accordance with the federal hemp program, so a product outside the definition should not be assumed to carry that protection in transit (Pub. L. 115-334, sec. 10114).

This does not mean every hemp product becomes unlawful. Industrial hemp remains within the definition. A final product that avoids the cannabinoid-source exclusions and stays at or below 0.4 milligrams of total THC and similar-effect cannabinoids per container can still qualify. The analysis is product by product.

Illinois did not adopt the federal delay

Public Act 104-0463 created the Illinois Hemp Act, codified at 410 ILCS 707, effective November 12, 2026. The Illinois definition of hemp tracks the federal section 781 definition, including the cannabinoid-source exclusions and the 0.4-milligram container limit, and the Illinois Act lists cannabinoids treated as having THC-like effects, including delta-8 THC, THC-P, HHC, and THC-O (Ill. Dep’t of Agriculture, Informational Bulletin IB-2026-06, June 2026).

In an October 2026 bulletin, the Illinois Department of Revenue said that consumable or topical products above 0.4 milligrams of total THC per container will be cannabis in Illinois beginning November 12, 2026, may be sold only under the Cannabis Regulation and Tax Act, and that the State plans to enforce on that date regardless of the federal delay (Ill. Dep’t of Revenue, Informational Bulletin FY 2027-04). Our companion briefing on Public Act 104-0463 covers the Illinois licensing, labeling, and testing rules in detail.

Building a federal classification record for each SKU

Classify actual products, not categories. For each SKU, record the cannabinoid profile from a batch-specific certificate of analysis, the source and production method of each cannabinoid, whether the product is intermediate or final, the container configuration, and the total THC and similar-effect cannabinoids per container. Then assign three federal classifications: today, November 12 through December 10, and December 11 forward if the law does not change.

Keep the evidence behind each conclusion. A certificate of analysis that reports only delta-9 THC will not answer a total-THC or cannabinoid-source question. Supplier agreements should require disclosure of cannabinoid source and production method, access to batch and formulation records, and a clear allocation of costs for holds, returns, and relabeling if the classification changes. Those are risk-management choices, not statutory requirements, but the statute turns on facts that only the supply chain can document.

Developments to monitor before December 11

Watch for any bill text that amends section 2019 or section 781, particularly in funding legislation moving in early December. Watch for FDA publication of the section 781 lists and container guidance, and for any U.S. Department of Agriculture action implementing the definition for growers. For a SKU-level working tool, use our hemp product compliance worksheet. Track the law in every state where a product is sold, because state hemp definitions do not all change on the federal schedule.

Questions to discuss with counsel

Which of our SKUs contain any cannabinoid whose natural-production status is disputed, and what evidence supports our classification? Which products exceed 0.4 milligrams per container under the December 11 test, and can the container be reconfigured lawfully? What inventory is committed in channels that cross state lines after December 10? Do our supply and distribution agreements allocate the cost of a classification change? For Illinois sales, what must stop on November 12 even though the federal date is later?